Wells Fargo & Company Ascendis Pharma A/S Put Options Transaction History
Wells Fargo & Company
- $407 Billion
- Q2 2024
Put Options
0 transactions
| Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
|---|
Others Institutions Holding ASND
# of Institutions
227Shares Held
56.7MCall Options Held
138KPut Options Held
249K-
Ra Capital Management, L.P. Boston, MA10.1MShares$1.26 Billion20.78% of portfolio
-
Westfield Capital Management CO LP Boston, MA4.96MShares$617 Million3.41% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI4.3MShares$534 Million0.93% of portfolio
-
Avoro Capital Advisors LLC New York, NY4.2MShares$522 Million7.81% of portfolio
-
Janus Henderson Group PLC London, X03.92MShares$487 Million0.29% of portfolio
About Ascendis Pharma A/S
- Ticker ASND
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,810,200
- Market Cap $6.94B
- Description
- Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...